ARTICLE | Company News
Medigen, Progen Industries deal
January 22, 2007 8:00 AM UTC
The companies ended their deal to develop PGL's PI-88 sulfated mannopentaose phosphate to treat cancer and cardiovascular disease (see BioCentury, June 5, 2000). The anti-angiogenic agent that inhibi...